Get the Stockscreener App
0.00
100.00%
-2.0301
Mural Oncology Plc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.0301
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$35.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
0.00 | 35.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Aug EndMonth: Is Mural Oncology plc part of any ETFJuly 2025 Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Ideas Watch: Will COHN benefit from government policyWeekly Stock Summary & Fast Gaining Stock Reports - baoquankhu1.vn
Is Mural Oncology plc affected by consumer sentimentTrade Performance Summary & Safe Entry Point Alerts - baoquankhu1.vn
Mural Oncology To Be Acquired By Xoma Royalty - MSN
RSI Check: Should I hold or sell Mural Oncology plc now2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Hedge Fund Moves: What are the future prospects of Brookfield Property Partners LPJuly 2025 Action & Risk Controlled Swing Alerts - baoquankhu1.vn
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus PT from Brokerages - Defense World
Risk Check: Is Mural Oncology plc affected by consumer sentimentCEO Change & Expert Curated Trade Ideas - baoquankhu1.vn
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
Will Mural Oncology plc stock outperform value stocks2025 AllTime Highs & Low Risk Entry Point Guides - ulpravda.ru
Will Mural Oncology plc stock outperform Nasdaq indexQuarterly Risk Review & AI Powered Trade Plan Recommendations - Улправда
Is Mural Oncology plc stock positioned for digital transformationQuarterly Profit Report & Community Consensus Picks - Улправда
How Mural Oncology plc stock compares to growth peersDollar Strength & Breakout Confirmation Alerts - ulpravda.ru
Retail Trends: Is Mural Oncology plc stock positioned for digital transformationGlobal Markets & Daily Oversold Stock Bounce Ideas - Улправда
Net debt of Mural Oncology Plc – LS:A3EE4M - TradingView — Track All Markets
Will Mural Oncology plc stock benefit from automation2026 world cup usa national team semifinals goalkeepers pressing system group prediction breakdown - Улправда
Return on invested capital % of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab - marketscreener.com
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
Net margin % of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
Current ratio of Mural Oncology Plc – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Earnings and Revenue – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Statistics – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Cash Flow – BER:IELK2BOB - TradingView — Track All Markets
MURA SEC FilingsMural Oncology PLC 10-K, 10-Q, 8-K Forms - Stock Titan
Mural Oncology Plc Balance Sheet – BER:IELK2BOB - TradingView — Track All Markets
Mural Oncology Plc Dividends – BER:IELK2BOB - TradingView — Track All Markets
Two XOMA preferred share classes pay cash to holders in January - Stock Titan
Entry Recap: How Mural Oncology plc stock reacts to oil prices2025 Pullback Review & Weekly Sector Rotation Insights - Улправда
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages - Defense World
How Mural Oncology plc stock reacts to oil pricesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - Улправда
Market Recap: Will Mural Oncology plc stock benefit from automationJuly 2025 Review & Real-Time Stock Movement Alerts - Улправда
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Xoma Navigates Clinical Setback with Strategic Acquisition - AD HOC NEWS
Xoma completes acquisition of Mural Oncology - MSN
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025) - FinancialContent
Mural Oncology shareholders approve acquisition by XRA 5 Corp. - MSN
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma Completes Acquisition of Mural Oncology - TipRanks
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative
Mural Oncology Plc Completes Acquisition by XRA 5 Corp. - TipRanks
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - Yahoo Finance
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan
Mural Oncology plc(NasdaqGM: MURA) dropped from S&P TMI Index - marketscreener.com
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):